Clinical Competition Candidate

ALVESCO

Respiratory · Asthma (inhaled corticosteroid)

ALVESCO carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 19 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

19months

to latest listed patent expiry (February 1, 2028)

Expiry attractiveness: 5/5

Patent profile

Substance patent (none)

Product / formulation patent (none)

Use-code patent (listed)

Patent count: 1

Complexity score: 1/5

Clinical competition

Score: 5/5

Active trials linked: 88

Phase 2/3 trials: 62

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: CICLESONIDE

Applicant (NDA holder): AZURITY PHARMACEUTICALS INC

Confidence: High

Market context

Therapeutic area: Respiratory

Indication: Asthma (inhaled corticosteroid)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.